S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
Log in

DURECT Stock Price, Forecast & Analysis (NASDAQ:DRRX)

$1.94
+0.03 (+1.57 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$1.81
Now: $1.94
$1.95
50-Day Range
$1.70
MA: $1.89
$2.14
52-Week Range
$0.46
Now: $1.94
$2.46
Volume721,200 shs
Average Volume791,974 shs
Market Capitalization$373.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.56 million
Book Value$0.11 per share

Profitability

Net Income$-25,320,000.00
Net Margins-105.07%

Miscellaneous

Employees88
Market Cap$373.18 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.


DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.03. The specialty pharmaceutical company had revenue of $10.76 million for the quarter, compared to the consensus estimate of $7.78 million. DURECT had a negative net margin of 105.07% and a negative return on equity of 119.34%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

3 Wall Street analysts have issued 1 year price targets for DURECT's stock. Their forecasts range from $2.10 to $5.00. On average, they anticipate DURECT's stock price to reach $3.53 in the next year. This suggests a possible upside of 82.1% from the stock's current price. View Analyst Price Targets for DURECT.

What is the consensus analysts' recommendation for DURECT?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

Has DURECT been receiving favorable news coverage?

Media headlines about DRRX stock have been trending neutral on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DURECT earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for DURECT.

Are investors shorting DURECT?

DURECT saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,250,000 shares, an increase of 28.7% from the September 30th total of 971,000 shares. Based on an average trading volume of 790,200 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.8% of the shares of the stock are short sold. View DURECT's Current Options Chain.

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (4.27%), Tocqueville Asset Management L.P. (0.59%), Assenagon Asset Management S.A. (0.23%), California Public Employees Retirement System (0.16%), SG Americas Securities LLC (0.05%) and Commonwealth Equity Services LLC (0.01%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Tower Research Capital LLC TRC and SG Americas Securities LLC. View Insider Buying and Selling for DURECT.

Which major investors are buying DURECT stock?

DRRX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., California Public Employees Retirement System, Tocqueville Asset Management L.P. and Commonwealth Equity Services LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.94.

How big of a company is DURECT?

DURECT has a market capitalization of $373.18 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.

What is DURECT's official website?

The official website for DURECT is http://www.durect.com/.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.


MarketBeat Community Rating for DURECT (NASDAQ DRRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel